Conditions: Methicillin Resistant Staphylococcus Aureus (MRSA)
Keywords: Staphylococcal pneumonia Methicillin-resistant staphylococcal pneumonia healthcare-associated pneumonia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1225
Healthy volunteers: no

Brief summary:
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

Detailed description:

Arms:
arm 1: Subjects receiving linezolid for the treatment phase of the study arm 2: Subjects receiving vancomycin for the treatment phase of the study

Interventions: intervention 1: linezolid (Zyvox) intervention 2: vancomycin
Intervention descriptions: intervention 1: Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion. intervention 2: Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.

Protocol document: